Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced
Primary endpoint of safety and tolerability met successfully Positive impact on exploratory clinical efficacy parameters: REVEAL risk score: 43% (9/21) of
Chesterbrook, Pa., United States: Neuraptive Therapeutics Inc., a leading biopharmaceutical company focused on novel treatments for peripheral nerve injuries, today
Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.
Copyright© 2025 Creative Bharat Powered By A Buzz Company